<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39444892</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>Opportunity for severe and critical COVID-19 pneumonia treatment with corticosteroids: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>5688</StartPage><EndPage>5697</EndPage><MedlinePgn>5688-5697</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/jtd-24-329</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The coronavirus disease 2019 (COVID-19) pandemic has been the most significant infectious disease outbreak worldwide in the past 3 years, with the potential to progress to severe pneumonia and trigger systemic inflammatory response, posing a threat to human health and life. This study aims to explore the use of corticosteroids for COVID-19 and provide recommendations on the timing and dosage of the treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a retrospective cohort study, enrolling 100 with COVID-19 pneumonia between December 2022 and January 2023. The diagnosis of severe and critical COVID-19 pneumonia patients was according to China's Ninth Edition of the Diagnosis and Treatment Plan for COVID-19 Pneumonia. T test and univariate proportional hazard analysis were employed to investigate the opportunity of corticosteroids therapy in relation to patients' prognosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Compared to COVID-19 pneumonia patients treated with corticosteroids in the early phase, those who received late-phase corticosteroid therapy had a higher proportion of intensive care unit (ICU) admission (P=0.01), longer hospital stay (P=0.006), lower in-hospital survival rate (P=0.03), and slower recovery (P&lt;0.001). A significant difference was also observed in logistic univariate proportional hazard analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The early administration of corticosteroid therapy has been shown to significantly improve the prognosis of COVID-19 pneumonia patients, promoting recovery with significant clinical significance. Our recommendation for the administration of corticosteroid therapy is to be applied on the 6th-9th day of persisting unrelieved symptoms of COVID-19 pneumonia.</AbstractText><CopyrightInformation>2024 AME Publishing Company. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Peking Union Medical College &amp; Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, Puren Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zong</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Emergency, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Huadong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shengyong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0003-5253-1567</Identifier><AffiliationInfo><Affiliation>Department of Emergency, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019 pneumonia (COVID-19 pneumonia)</Keyword><Keyword MajorTopicYN="N">corticosteroids</Keyword><Keyword MajorTopicYN="N">hospital length of stay</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-329/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39444892</ArticleId><ArticleId IdType="pmc">PMC11494557</ArticleId><ArticleId IdType="doi">10.21037/jtd-24-329</ArticleId><ArticleId IdType="pii">jtd-16-09-5688</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Attaway AH, Scheraga RG, Bhimraj A, et al. Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ 2021;372:n436. 10.1136/bmj.n436</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n436</ArticleId><ArticleId IdType="pubmed">33692022</ArticleId></ArticleIdList></Reference><Reference><Citation>Salian VS, Wright JA, Vedell PT, et al. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Mol Pharm 2021;18:754-71. 10.1021/acs.molpharmaceut.0c00608</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.0c00608</ArticleId><ArticleId IdType="pubmed">33464914</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliano P, Sellitto C, Conti V, et al. Characteristics of viral pneumonia in the COVID-19 era: an update. Infection 2021;49:607-16. 10.1007/s15010-021-01603-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01603-y</ArticleId><ArticleId IdType="pmc">PMC8006879</ArticleId><ArticleId IdType="pubmed">33782861</ArticleId></ArticleIdList></Reference><Reference><Citation>Vadász I, Husain-Syed F, Dorfmüller P, et al. Severe organising pneumonia following COVID-19. Thorax 2021;76:201-4. 10.1136/thoraxjnl-2020-216088</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216088</ArticleId><ArticleId IdType="pubmed">33177230</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Saber Batiha G, Al-Gareeb AI, Saad HM, et al. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology 2022;30:1189-205. 10.1007/s10787-022-00987-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00987-z</ArticleId><ArticleId IdType="pmc">PMC9106274</ArticleId><ArticleId IdType="pubmed">35562628</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng QH, Dong PL, Guo YB, et al. Use of glucocorticoid in treatment of severe acute respiratory syndrome cases. Zhonghua Yu Fang Yi Xue Za Zhi 2003;37:233-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12930669</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao JZ, Ma L, Gao J, et al. Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy. Zhonghua Nei Ke Za Zhi 2004;43:179-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059370</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Annane D, Chrousos GP, et al. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest 2009;136:1631-43. 10.1378/chest.08-2408</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.08-2408</ArticleId><ArticleId IdType="pubmed">19801579</ArticleId></ArticleIdList></Reference><Reference><Citation>Dube T, Ghosh A, Mishra J, et al. Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. Adv Ther (Weinh) 2021;4:2000172. 10.1002/adtp.202000172</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adtp.202000172</ArticleId><ArticleId IdType="pmc">PMC7645867</ArticleId><ArticleId IdType="pubmed">33173808</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A, Davoli C, Borrazzo C, et al. Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. Biomedicines 2022;10:1548. 10.3390/biomedicines10071548</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10071548</ArticleId><ArticleId IdType="pmc">PMC9312892</ArticleId><ArticleId IdType="pubmed">35884852</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexamethasone for COVID-19: preliminary findings. Drug Ther Bull 2020;58:133. 10.1136/dtb.2020.000045</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/dtb.2020.000045</ArticleId><ArticleId IdType="pubmed">32690491</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Feng YM, Ni JX, et al. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration 2021;100:116-26. 10.1159/000512063</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512063</ArticleId><ArticleId IdType="pmc">PMC7900459</ArticleId><ArticleId IdType="pubmed">33486496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta J, Rolta R, Mehta BB, et al. Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review. Front Microbiol 2022;13:813358. 10.3389/fmicb.2022.813358</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.813358</ArticleId><ArticleId IdType="pmc">PMC8886296</ArticleId><ArticleId IdType="pubmed">35242118</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur M, Datusalia AK, Kumar A. Use of steroids in COVID-19 patients: A meta-analysis. Eur J Pharmacol 2022;914:174579. 10.1016/j.ejphar.2021.174579</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174579</ArticleId><ArticleId IdType="pmc">PMC8525014</ArticleId><ArticleId IdType="pubmed">34678244</ArticleId></ArticleIdList></Reference><Reference><Citation>Calzetta L, Aiello M, Frizzelli A, et al. Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. J Clin Med 2021;10:1607. 10.3390/jcm10081607</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10081607</ArticleId><ArticleId IdType="pmc">PMC8069656</ArticleId><ArticleId IdType="pubmed">33920093</ArticleId></ArticleIdList></Reference><Reference><Citation>Covid-19 pneumonia diagnosis and treatment guideline (Trial 9th edition). Available online: https://covid19treatmentguidelines.nih.gov/</Citation></Reference><Reference><Citation>Huang J, Xuan D, Li X, et al. The value of APACHE II in predicting mortality after paraquat poisoning in Chinese and Korean population: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6838. 10.1097/MD.0000000000006838</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000006838</ArticleId><ArticleId IdType="pmc">PMC5627797</ArticleId><ArticleId IdType="pubmed">28746171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambden S, Laterre PF, Levy MM, et al. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care 2019;23:374. 10.1186/s13054-019-2663-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2663-7</ArticleId><ArticleId IdType="pmc">PMC6880479</ArticleId><ArticleId IdType="pubmed">31775846</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S. Calculated decisions: CURB-65 score for pneumonia severity. Emerg Med Pract 2021;23:CD1-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33529515</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev 2021;170:1-25. 10.1016/j.addr.2020.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.12.011</ArticleId><ArticleId IdType="pmc">PMC7759095</ArticleId><ArticleId IdType="pubmed">33359141</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabó GT, Mahiny AJ, Vlatkovic I. COVID-19 mRNA vaccines: Platforms and current developments. Mol Ther 2022;30:1850-68. 10.1016/j.ymthe.2022.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.016</ArticleId><ArticleId IdType="pmc">PMC8856755</ArticleId><ArticleId IdType="pubmed">35189345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta E, Padhi A, Khodare A, et al. Pooled RNA sample reverse transcriptase real time PCR assay for SARS CoV-2 infection: A reliable, faster and economical method. PLoS One 2020;15:e0236859. 10.1371/journal.pone.0236859</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236859</ArticleId><ArticleId IdType="pmc">PMC7392263</ArticleId><ArticleId IdType="pubmed">32730368</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2004;101:15748-53. 10.1073/pnas.0403812101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0403812101</ArticleId><ArticleId IdType="pmc">PMC524836</ArticleId><ArticleId IdType="pubmed">15496474</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelamkavil S, Arison B, Birzin E, et al. Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSST2 and hSST4. An unexpected effect of the chirality of Trp8 on NMR spectra in methanol. J Med Chem 2005;48:4025-30. 10.1021/jm058184l</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm058184l</ArticleId><ArticleId IdType="pubmed">15943475</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523-34. 10.1038/nrmicro.2016.81</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2016.81</ArticleId><ArticleId IdType="pmc">PMC7097822</ArticleId><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim CJ, Choi WS, Jung Y, et al. Surveillance of the Middle East respiratory syndrome (MERS) coronavirus (CoV) infection in healthcare workers after contact with confirmed MERS patients: incidence and risk factors of MERS-CoV seropositivity. Clin Microbiol Infect 2016;22:880-6. 10.1016/j.cmi.2016.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2016.07.017</ArticleId><ArticleId IdType="pmc">PMC7128923</ArticleId><ArticleId IdType="pubmed">27475739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Chang SY, Sung M, et al. Extensive Viable Middle East Respiratory Syndrome (MERS) Coronavirus Contamination in Air and Surrounding Environment in MERS Isolation Wards. Clin Infect Dis 2016;63:363-9. 10.1093/cid/ciw239</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw239</ArticleId><ArticleId IdType="pmc">PMC7108054</ArticleId><ArticleId IdType="pubmed">27090992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KH, Tandi TE, Choi JW, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect 2017;95:207-13. 10.1016/j.jhin.2016.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2016.10.008</ArticleId><ArticleId IdType="pmc">PMC7114867</ArticleId><ArticleId IdType="pubmed">28153558</ArticleId></ArticleIdList></Reference><Reference><Citation>Yam C, Yen EY, Chang JT, et al. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 2021;27:5365-75. 10.1158/1078-0432.CCR-21-0144</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-0144</ArticleId><ArticleId IdType="pmc">PMC8752638</ArticleId><ArticleId IdType="pubmed">34253579</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalhoub S, Al-Hameed F, Mandourah Y, et al. Critically ill healthcare workers with the middle east respiratory syndrome (MERS): A multicenter study. PLoS One 2018;13:e0206831. 10.1371/journal.pone.0206831</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0206831</ArticleId><ArticleId IdType="pmc">PMC6237307</ArticleId><ArticleId IdType="pubmed">30439974</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi YM, Al-Omari A, Mandourah Y, et al. Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. Crit Care Med 2017;45:1683-95. 10.1097/CCM.0000000000002621</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002621</ArticleId><ArticleId IdType="pubmed">28787295</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-43. 10.1001/jamainternmed.2020.0994</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Zhang H, Wu Q, et al. Sestrin 2 protects against LPS-induced acute lung injury by inducing mitophagy in alveolar macrophages. Life Sci 2021;267:118941. 10.1016/j.lfs.2020.118941</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118941</ArticleId><ArticleId IdType="pubmed">33359748</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JR. Steroids for early acute respiratory distress syndrome: critical appraisal of Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131:954-963. Pediatr Crit Care Med 2010;11:404-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19838137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JL, Shi SR, Ma XL, et al. Clinical management of sepsis resulting from infections including COVID-19. Discov Med 2020;29:201-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33007195</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SS, Zhou X, Lin XG, et al. Experience of Clinical Management for Pregnant Women and Newborns with Novel Coronavirus Pneumonia in Tongji Hospital, China. Curr Med Sci 2020;40:285-9. 10.1007/s11596-020-2174-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11596-020-2174-4</ArticleId><ArticleId IdType="pmc">PMC7100444</ArticleId><ArticleId IdType="pubmed">32219626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061-9. 10.1001/jama.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group , Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693-704. 10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group ; Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020;324:1330-41. 10.1001/jama.2020.17023</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>